View ValuationHeXun Biosciences 将来の成長Future 基準チェック /06現在、 HeXun Biosciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長22.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$48.00, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Total loss to shareholders of 36% over the past year.Reported Earnings • Apr 06Full year 2025 earnings released: EPS: NT$2.43 (vs NT$3.20 in FY 2024)Full year 2025 results: EPS: NT$2.43 (down from NT$3.20 in FY 2024). Revenue: NT$293.2m (up 2.4% from FY 2024). Net income: NT$111.9m (down 24% from FY 2024). Profit margin: 38% (down from 51% in FY 2024). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$58.90, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Life Sciences industry in Asia. Total loss to shareholders of 29% over the past year.お知らせ • Mar 13HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city TaiwanReported Earnings • Dec 30Third quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.76 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.29 (down from NT$0.76 in 3Q 2024). Revenue: NT$56.6m (down 26% from 3Q 2024). Net income: NT$13.6m (down 61% from 3Q 2024). Profit margin: 24% (down from 46% in 3Q 2024). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 21x in the Life Sciences industry in Taiwan. Total loss to shareholders of 13% over the past year.New Risk • Aug 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.98b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (NT$2.98b market cap, or US$99.2m).New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (NT$3.28b market cap, or US$99.1m).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$70.00, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 26x in the Life Sciences industry in Taiwan. Total returns to shareholders of 19% over the past year.Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$3.20 (vs NT$0.74 in FY 2023)Full year 2024 results: EPS: NT$3.20 (up from NT$0.74 in FY 2023). Revenue: NT$286.4m (up 119% from FY 2023). Net income: NT$147.2m (up 340% from FY 2023). Profit margin: 51% (up from 26% in FY 2023). The increase in margin was driven by higher revenue.お知らせ • Mar 19HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025, at 09:30 Taipei Standard Time. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city TaiwanNew Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change).Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$89.50, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 29x in the Life Sciences industry in Taiwan. Total returns to shareholders of 60% over the past year.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).Valuation Update With 7 Day Price Move • Dec 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Negligible returns to shareholders over past year.New Risk • Nov 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m).お知らせ • Mar 29HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024.New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (NT$3.14b market cap, or US$98.7m). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、HeXun Biosciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6986 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025293112135164N/A9/30/2025291112156178N/A6/30/2025304131152175N/A3/31/2025295139118148N/A12/31/202428614784121N/A9/30/202425513370111N/A6/30/20242361243067N/A3/31/2024183792655N/A12/31/2023131332243N/A9/30/2023103131229N/A6/30/202375-7215N/A3/31/202362-6313N/A12/31/202249-5411N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6986の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6986の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6986の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6986の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6986の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6986の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 13:15終値2026/07/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HeXun Biosciences Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$48.00, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Total loss to shareholders of 36% over the past year.
Reported Earnings • Apr 06Full year 2025 earnings released: EPS: NT$2.43 (vs NT$3.20 in FY 2024)Full year 2025 results: EPS: NT$2.43 (down from NT$3.20 in FY 2024). Revenue: NT$293.2m (up 2.4% from FY 2024). Net income: NT$111.9m (down 24% from FY 2024). Profit margin: 38% (down from 51% in FY 2024). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$58.90, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Life Sciences industry in Asia. Total loss to shareholders of 29% over the past year.
お知らせ • Mar 13HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city Taiwan
Reported Earnings • Dec 30Third quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.76 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.29 (down from NT$0.76 in 3Q 2024). Revenue: NT$56.6m (down 26% from 3Q 2024). Net income: NT$13.6m (down 61% from 3Q 2024). Profit margin: 24% (down from 46% in 3Q 2024). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 21x in the Life Sciences industry in Taiwan. Total loss to shareholders of 13% over the past year.
New Risk • Aug 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.98b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (NT$2.98b market cap, or US$99.2m).
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (NT$3.28b market cap, or US$99.1m).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$70.00, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 26x in the Life Sciences industry in Taiwan. Total returns to shareholders of 19% over the past year.
Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$3.20 (vs NT$0.74 in FY 2023)Full year 2024 results: EPS: NT$3.20 (up from NT$0.74 in FY 2023). Revenue: NT$286.4m (up 119% from FY 2023). Net income: NT$147.2m (up 340% from FY 2023). Profit margin: 51% (up from 26% in FY 2023). The increase in margin was driven by higher revenue.
お知らせ • Mar 19HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025, at 09:30 Taipei Standard Time. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city Taiwan
New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change).
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$89.50, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 29x in the Life Sciences industry in Taiwan. Total returns to shareholders of 60% over the past year.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Negligible returns to shareholders over past year.
New Risk • Nov 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m).
お知らせ • Mar 29HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024.
New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (NT$3.14b market cap, or US$98.7m).